Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Partner
Lundbeckfond Ventures - Copenhagen, Denmark
Director, IT Global Operation Services, End-User Informatics Job
Celgene Corporation - Summit, NJ, US
Principal Scientist
Watson Pharmaceuticals - Fort Lauderdale, FL
Associate Director, Global Production Planning & Inventory Control Job
Celgene Corporation - Basking Ridge, NJ, US
Clinical Trials Site Director
Lovelace Respiratory Research Institute - Albuquerque, NM

More Jobs >>

Events

Biomarker Applications for Improved Clinical Trial Outcomes
Nov. 15-16 — Boston
Partnerships in Clinical Trials 2012
March 4-7 — Orlando, FL
Pharmacovigilance and Risk Management Strategies 2012
January 22-25, 2012 — Arlington, Virginia
Just Released: New Trends in Preventive and Therapeutic Vaccine

More Events >>

Related Tags >> BioCryst

peramivir News

Most Popular peramivir Story

Vax crisis could spur swift peramivir approval

October 22, 2009 — 7:49am ET | By John Carroll

There's been a considerable amount of speculation about which of the new flu vaccine and antiviral technologies now in the clinic will benefit from the swine flu outbreak and the outcry it has Read more...

peramivir Press Releases

BioCryst to Present at Jefferies 2010 Global Life Sciences Conference
BioCryst Reports First Quarter 2010 Financial Results and Provides Corporate Update
BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
PRESS RELEASE: BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza

Latest Headlines

Vax crisis could spur swift peramivir approval
October 22, 2009
BioCryst outlines Phase III plans for peramivir
October 1, 2009

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK